SCHEMBL29173447

SCHEMBL29173447

CNc1nc(Nc2cccc(N3CCNCC3)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 11/20 0.40
▸ CCNA2 P20248 10/20 0.40
▸ CDK4 P11802 1/20 0.40
▸ CCND3 P30281 1/20 0.40
▸ CDK6 Q00534 1/20 0.40
▸ MARK3 P27448 1/20 0.38
▸ CDK9 P50750 10/20 0.38
▸ CCNT1 O60563 9/20 0.38
▸ CDK1 P06493 7/20 0.38
▸ CCNB1 P14635 7/20 0.38
▸ CDK7 P50613 7/20 0.38
▸ CCNH P51946 7/20 0.38
▸ CCNA1 P78396 5/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ BTK Q06187 1/20 0.37
▸ ALK Q9UM73 3/20 0.36
▸ TTK P33981 1/20 0.35
▸ EML4 Q9HC35 1/20 0.35
▸ EGFR P00533 1/20 0.35
▸ PIM1 P11309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30205989 1.00 CDK2 (0.40) CDK2CCNA2CDK4CCND3CDK6
SCHEMBL29173496 0.93 EML4 (0.42) CDK2CCNA2CDK9CCNT1CDK1
SCHEMBL29173546 0.88 JAK2 (0.42) CDK2CCNA2CCND3CDK6CDK9
SCHEMBL30206211 0.88 JAK2 (0.42) CDK2CCNA2CCND3CDK6CDK9
SCHEMBL29173534 0.86 ALK (0.36) ALKEGFRJAK2JAK3PTK2
SCHEMBL24944460 0.84 EML4 (0.51) CDK2CCNA2CDK4CCND3CDK6
SCHEMBL30205535 0.84 EML4 (0.51) CDK2CCNA2CDK4CCND3CDK6
SCHEMBL29173378 0.84 CYP1A2 (0.35) CDK2CCNA2CDK4CCND3CDK6
SCHEMBL30206107 0.84 CYP1A2 (0.35) CDK2CCNA2CDK4CCND3CDK6
SCHEMBL29173512 0.82 PKMYT1 (0.40) CDK2CCNA2CDK4CCND3CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
Send feedback